Effect of Tocilizumab Treatment on Seroconversion in Hyperinflammation Secondary to Covid 19

Faruk Karandere; Deniz Yılmaz; Felemez Arslan; Ezgi Şahin; Hakan Koçoğlu; Nilgün Işıksaçan

Makale detayları

Effect of Tocilizumab Treatment on Seroconversion in Hyperinflammation Secondary to Covid 19

Yazarlar:

Faruk Karandere | Deniz Yılmaz | Felemez Arslan | Ezgi Şahin | Hakan Koçoğlu | Nilgün Işıksaçan

Yayıncı:

Alanya Alaaddin Keykubat Üniversitesi

Ana Başlıklar:

İç Hastalıkları | Klinik Kimya | Klinik Mikrobiyoloji

Dergi:

Acta Medica Alanya Vol.8 Issue 1, pp.39-44

Belge Tipi:

Makale

Yayın Tarihi:

4/2024

Belge Dili:

İngilizce

Document ID (Org No.):

2001316679

pISSN:

2587-0319

Anahtar kelimeler:

Özet:

 Aim:During the ongoing COVID-19 pandemic, the management of hyperinflammation, a serious symptom that occurs secondary to the disease, has emerged as a major challenge. Tocilizumab, an immunosuppressive drug, offers a potential solution. However, it is extremely important to understand its effects on antibody formation after recovery from Covid-19. Therefore, our study aimed to investigate the effects of tocilizumab treatment on antibody production by measuring SARS-COV-2 spike total antibody levels at the third month post-infection in patients receiving this specific treatment. Materyal and Methods:Our study incorporated 48 patients diagnosed with Covid 19 who presented with hyperinflammation during hospitalization. These patients, admitted to our institution, were treated with tocilizumab and subsequently discharged. We meticulously determined the 3rd month SARS-COV-2 spike total antibody levels in these patients. Results:The participants of the study, characterized by a mean age of 52.5  11.6 years, demonstrated positive SARS-COV-2 spike total antibody levels at 3 months, irrespective of age, gender, comorbidity, and length of hospital stay. The mean antibody levels in the patient population were quantified to be 223.58  68.36 UmL, with a range from 14.2 to 250 UmL. Conclusion: Our findings reveal that all patients exhibited positive antibody levels at 3 months following tocilizumab treatment.This suggests that the administration of tocilizumab in the management of hyperinflammation secondary to Covid 19 does not adversely affect antibody formation, at least in the short term. This could have substantial implications for future treatment strategies.

 Aim:During the ongoing COVID-19 pandemic, the management of hyperinflammation, a serious symptom that occurs secondary to the disease, has emerged as a major challenge. Tocilizumab, an immunosuppressive drug, offers a potential solution. However, it is extremely important to understand its effects on antibody formation after recovery from Covid-19. Therefore, our study aimed to investigate the effects of tocilizumab treatment on antibody production by measuring SARS-COV-2 spike total antibody levels at the third month post-infection in patients receiving this specific treatment. Materyal and Methods:Our study incorporated 48 patients diagnosed with Covid 19 who presented with hyperinflammation during hospitalization. These patients, admitted to our institution, were treated with tocilizumab and subsequently discharged. We meticulously determined the 3rd month SARS-COV-2 spike total antibody levels in these patients. Results:The participants of the study, characterized by a mean age of 52.5  11.6 years, demonstrated positive SARS-COV-2 spike total antibody levels at 3 months, irrespective of age, gender, comorbidity, and length of hospital stay. The mean antibody levels in the patient population were quantified to be 223.58  68.36 UmL, with a range from 14.2 to 250 UmL. Conclusion: Our findings reveal that all patients exhibited positive antibody levels at 3 months following tocilizumab treatment.This suggests that the administration of tocilizumab in the management of hyperinflammation secondary to Covid 19 does not adversely affect antibody formation, at least in the short term. This could have substantial implications for future treatment strategies.

 Aim:During the ongoing COVID-19 pandemic, the management of hyperinflammation, a serious symptom that occurs secondary to the disease, has emerged as a major challenge. Tocilizumab, an immunosuppressive drug, offers a potential solution. However, it is extremely important to understand its effects on antibody formation after recovery from Covid-19. Therefore, our study aimed to investigate the effects of tocilizumab treatment on antibody production by measuring SARS-COV-2 spike total antibody levels at the third month post-infection in patients receiving this specific treatment. Materyal and Methods:Our study incorporated 48 patients diagnosed with Covid 19 who presented with hyperinflammation during hospitalization. These patients, admitted to our institution, were treated with tocilizumab and subsequently discharged. We meticulously determined the 3rd month SARS-COV-2 spike total antibody levels in these patients. Results:The participants of the study, characterized by a mean age of 52.5  11.6 years, demonstrated positive SARS-COV-2 spike total antibody levels at 3 months, irrespective of age, gender, comorbidity, and length of hospital stay. The mean antibody levels in the patient population were quantified to be 223.58  68.36 UmL, with a range from 14.2 to 250 UmL. Conclusion: Our findings reveal that all patients exhibited positive antibody levels at 3 months following tocilizumab treatment.This suggests that the administration of tocilizumab in the management of hyperinflammation secondary to Covid 19 does not adversely affect antibody formation, at least in the short term. This could have substantial implications for future treatment strategies.

 Amaç:Devam eden COVID-19 pandemisi sürecinde, hastalığa ikincil olarak ortaya çıkan ciddi bir semptom olan hiperinflamasyonun yönetimi büyük bir meydan okuma olarak karşımıza çıkmıştır. İmmünsüpresif bir ilaç olan Tocilizumab, potansiyel bir çözüm sunmaktadır. Ancak, Covid-19dan iyileşme sonrası antikor oluşumu üzerindeki etkilerini anlamak son derece önemlidir. Bu nedenle, çalışmamız bu spesifik tedaviyi alan hastalarda, enfeksiyon sonrası üçüncü ayda SARS-COV-2 spike toplam antikor seviyelerini ölçerek, tocilizumab tedavisinin antikor üretimi üzerindeki etkilerini araştırmayı amaçlamıştır. Yöntemler: Çalışmamız, hastaneye yatırıldıkları sırada hiperinflamasyon gösteren ve Covid-19 tanısı almış 48 hastayı içermektedir. Bu hastalar kurumumuza kabul edilmiş, tocilizumab ile tedavi edilmiş ve sonrasında taburcu edilmişlerdir. Bu hastaların 3. ay SARS-COV-2 spike toplam antikor seviyeleri titizlikle belirlenmiştir. Bulgular: Çalışmanın katılımcıları, ortalama yaşları 52,5  11,6 olan, yaş, cinsiyet, komorbidite ve hastanede kalış süresi ne olursa olsun 3. ayda pozitif SARS-COV-2 spike toplam antikor seviyeleri göstermiştir. Hastaların ortalama antikor seviyeleri 223,58  68,36 UmL olarak ölçülmüş, aralık 14,2 ile 250 UmL arasında değişmiştir. Sonuç: Bulgularımız, tüm hastaların tocilizumab tedavisi sonrası 3 ayda pozitif antikor seviyeleri sergilediklerini ortaya koymaktadır. Bu, hiperinflamasyonun Covid 19a ikincil yönetiminde tocilizumab uygulamasının, en azından kısa vadede, antikor oluşumunu olumsuz etkilemediğini göstermektedir. Bu, gelecekteki tedavi stratejileri için önemli sonuçlar doğurabilir.

Makale detayları

Effect of Tocilizumab Treatment on Seroconversion in Hyperinflammation Secondary to Covid 19

Yazarlar:

Faruk Karandere | Deniz Yılmaz | Felemez Arslan | Ezgi Şahin | Hakan Koçoğlu | Nilgün Işıksaçan

Yayıncı:

Alanya Alaaddin Keykubat Üniversitesi

Ana Başlıklar:

İç Hastalıkları | Klinik Kimya | Klinik Mikrobiyoloji

Dergi:

Acta Medica Alanya Vol.8 Issue 1, pp.39-44

Belge Tipi:

Makale

Yayın Tarihi:

4/2024

Belge Dili:

İngilizce

Document ID (Org No.):

2001316679

pISSN:

2587-0319

COVID-19

IL-6

Hyperinflammation

Tocilizumab

AntibodyCovid 19

IL-6

Hiperinflamasyon

Tocilizumab

Antikor

Sayı

Makale detayları

Yazarlar: Faruk Karandere | Deniz Yılmaz | Felemez Arslan | Ezgi Şahin | Hakan Koçoğlu | Nilgün Işıksaçan

Yayıncı: Alanya Alaaddin Keykubat Üniversitesi

Ana Başlıklar: İç Hastalıkları | Klinik Kimya | Klinik Mikrobiyoloji

Dergi: Acta Medica Alanya Vol.8 Issue 1, pp.39-44

Belge Tipi: Makale

Yayın Tarihi: 4/2024

Belge Dili: İngilizce

Document ID (Org No.): 2001316679

pISSN: 2587-0319

Sayı

Yazarlar:

Faruk Karandere | Deniz Yılmaz | Felemez Arslan | Ezgi Şahin | Hakan Koçoğlu | Nilgün Işıksaçan

Yayıncı:

Alanya Alaaddin Keykubat Üniversitesi

Ana Başlıklar:

İç Hastalıkları | Klinik Kimya | Klinik Mikrobiyoloji

Dergi:

Acta Medica Alanya Vol.8 Issue 1, pp.39-44

Belge Tipi:

Makale

Yayın Tarihi:

4/2024

Belge Dili:

İngilizce

Document ID (Org No.):

2001316679

pISSN:

2587-0319